Effect of the tyrosine kinase inhibitors on the growth in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case-control study

作者全名："Cai, Jiaoyang; Liu, Hu; Chen, Yumei; Yu, Jie; Gao, Ju; Jiang, Hua; Zhai, Xiaowen; Ju, Xiuli; Wu, Xuedong; Wang, Ningling; Tian, Xin; Liang, Changda; Fang, Yongjun; Zhou, Fen; Li, Hong; Sun, Lirong; Yang, Liangchun; Guo, Jing; Liu, Aiguo; Li, Chi-kong; Zhu, Yiping; Tang, Jingyan; Yang, Jun J.; Shen, Shuhong; Cheng, Cheng; Pui, Ching-Hon"

作者地址："[Cai, Jiaoyang; Tang, Jingyan; Shen, Shuhong] Shanghai Jiao Tong Univ, Shanghai Childrens Med Ctr, Dept Hematol Oncol, Key Lab Pediat Hematol & Oncol,Sch Med, Shanghai, Peoples R China; [Cai, Jiaoyang; Tang, Jingyan; Shen, Shuhong] Natl Childrens Med Ctr, Shanghai, Peoples R China; [Liu, Hu] Soochow Univ, Childrens Hosp, Dept Hematol Oncol, Suzhou, Peoples R China; [Liu, Hu] Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp, Tianjin, Peoples R China; [Chen, Yumei] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol, Natl Clin Res Ctr Blood Dis, Dept Pediat,State Key Lab Expt Hematol, Tianjin, Peoples R China; [Yu, Jie] Chongqing Med Univ, Dept Hematol Oncol, Affiliated Childrens Hosp, Chongqing, Peoples R China; [Gao, Ju; Zhu, Yiping] Sichuan Univ, West China Univ Hosp 2, Dept Pediat, Key Lab Birth Defects & Related,Minist Educ, Chengdu, Peoples R China; [Jiang, Hua] Guangzhou Women & Childrens Med Ctr, Dept Hematol Oncol, Guangzhou, Peoples R China; [Zhai, Xiaowen] Fudan Univ, Dept Hematol Oncol, Childrens Hosp, Shanghai, Peoples R China; [Ju, Xiuli] Shandong Univ, Qilu Hosp, Dept Pediat, Jinan, Peoples R China; [Wu, Xuedong] Southern Med Univ, Nanfang Hosp, Dept Pediat, Guangzhou, Peoples R China; [Wang, Ningling] Anhui Med Univ, Dept Pediat, Affiliated Hosp 2, Hefei, Anhui, Peoples R China; [Tian, Xin] KunMing Childrens Hosp, Dept Hematol Oncol, Kunming, Peoples R China; [Liang, Changda] Jiangxi Prov Childrens Hosp, Dept Hematol Oncol, Nanchang, Peoples R China; [Fang, Yongjun] Nanjing Med Univ, Childrens Hosp, Dept Hematol Oncol, Nanjing, Peoples R China; [Zhou, Fen] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Pediat, Wuhan, Peoples R China; [Li, Hong] Shanghai Childrens Hosp, Dept Hematol Oncol, Shanghai, Peoples R China; [Sun, Lirong] Qingdao Univ, Affiliated Hosp, Dept Pediat, Qingdao, Peoples R China; [Yang, Liangchun] Cent South Univ, Xiangya Hosp, Dept Pediat, Changsha, Peoples R China; [Gao, Ju] Xian Northwest Womens & Childrens Hosp, Dept Hematol Oncol, Xian, Peoples R China; [Liu, Aiguo] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Pediat, Wuhan, Peoples R China; [Pui, Ching-Hon] Chinese Univ Hong Kong, Hong Kong Childrens Hosp, Dept Pediat, Hong Kong, Peoples R China; [Yang, Jun J.] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN USA; [Cheng, Cheng] St Jude Childrens Res Hosp, Dept Biostat, Memphis, TN USA; [Pui, Ching-Hon] St Jude Childrens Res Hosp, Dept Oncol, Memphis, TN USA; [Pui, Ching-Hon] St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN USA; [Pui, Ching-Hon] St Jude Childrens Res Hosp, Dept Global Pediat Med, Memphis, TN USA; [Pui, Ching-Hon] St Jude Childrens Res Hosp, Dept Oncol Pathol & Global Pediat Med, Memphis, TN 38105 USA"

通信作者："Pui, CH (通讯作者)，St Jude Childrens Res Hosp, Dept Oncol Pathol & Global Pediat Med, Memphis, TN 38105 USA."

来源：LANCET REGIONAL HEALTH-WESTERN PACIFIC

ESI学科分类：　

WOS号：WOS:001092458300001

JCR分区：Q1

影响因子：7.6

年份：2023

卷号：38

期号：　

开始页：　

结束页：　

文献类型：Article

关键词：Tyrosine kinase inhibitor; Dasatinib; Imatinib; Philadelphia chromosome-positive leukemia; Acute lymphoblastic leukemia; Height; Growth; Puberty

摘要："Background First-generation ABL-targeted tyrosine kinase inhibitor (TKI) imatinib is known to retard growth in children but it is not known if the second-generation ABL-targeted TKI dasatinib has the same effect. We aimed to determine the impact of the first-or second-generation TKI on the growth of children treated for Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia (ALL).Methods We evaluated the longitudinal growth changes in 140 children with Ph+ ALL treated with imatinib or dasatinib in additional to intensive cytotoxic chemotherapy and 280 matched controls treated with the same intensity of cytotoxic chemotherapy without TKI on Chinese Children's Cancer Group ALL-2015 protocol between 2015 and 2019. We retrospectively reviewed the height data obtained during routine clinic visits at 4 time points: at diagnosis, the end of therapy, 1 year and 2 years off therapy. Height z Scores were derived with the aid of WHO Anthro version 3.2.2 and WHO AnthroPlus version 1.0.4, global growth monitoring tool. Findings This study consisted only patients who have completed all treatment in continuous complete remission without major events, including 33 patients randomized to receive imatinib, 43 randomized to receive dasatinib, and 64 assigned to receive dasatinib. Similar degree of loss of height z scores from diagnosis to the end of therapy was observed for the 33 imatinib-and the 107 dasatinib-treated patients (median 0 = -0.84 vs. -0.88, P = 0.41). Adjusting for height z score at diagnosis, puberty status, and sex, there was no significant difference in the longitudinal mean height z scores between patients treated with imatinib and those with dasatinib (0.08, 95% CI, -0.22 to 0.38, P = 0.60). The degree of loss of height z scores from diagnosis to end of therapy was significantly greater in the 140 TKI-treated patients than the 280 controls (median 0 = -0.88 vs. -0.18, P < 0.001). The longitudinal mean height z scores in the TKI-treated patients were significantly lower than those of the controls (-0.84, 95% CI, -0.98 to -0.69; P < 0.001). Interpretation These data suggest that dasatinib and imatinib have the similar adverse impact on the growth of children with Ph+ ALL. Funding This study was supported by the National Natural Science Foundation of China (grant 81670136 [JCai and JT]), the fourth round of Three-Year Public Health Action Plan (2015-2017; GWIV-25 [SS]), Shanghai Health Commission Clinical Research Project (202140161 [JCai]), the US National Cancer institute (CA21765 [C-H Pui]), and the American Lebanese Syrian Associated Charities (CC, JJY, and C-HP). The content of this paper is solely the responsibility of the authors and does not necessarily represent the official views of the US National Institutes of Health.Copyright (c) 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)."

基金机构：National Natural Science Foundation of China [81670136]; Three-Year Public Health Action Plan (2015-2017) [GWIV-25 [SS]]; Shanghai Health Commission Clinical Research Project [202140161]; US National Cancer institute [CA21765]; American Lebanese Syrian Associated Charities

基金资助正文："This study was supported by the National Natural Science Foundation of China (grant 81670136 [JCai and JT]), the fourth round of Three-Year Public Health Action Plan (2015-2017; GWIV-25 [SS]), Shanghai Health Commission Clinical Research Project (202140161 [JCai]), the US National Cancer institute (CA21765 [C-H Pui]), and the American Lebanese Syrian Associated Charities (CC, JJY, and C-HP). The content of this paper is solely the responsibility of the authors and does not necessarily represent the official views of the US National Institutes of Health."